We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

The Medicines for All Initiative: A Flow-based Synthesis of Nevirapine

Video   May 04, 2016

 


About the Speaker
Dr. Frank Gupton is a professor at Virginia Commonwealth University and holds joint appointments in the Departments of Chemistry and the Department of Chemical and Life Science Engineering. He also serves as Department Chair of the Chemical and Life Science Engineering Department and is the Director of the Institute for Engineering and Medicine at VCU. Dr. Gupton received his Bachelor’s of Science degree in chemistry from the University of Richmond and graduate degrees in organic chemistry from Georgia Tech and Virginia Commonwealth University. His thirty year industrial career has centered on the development and commercialization of chemical processes for pharmaceutical and agricultural applications. As Executive Director of Chemical Process Development at Boehringer Ingelheim Pharmaceuticals he led the development and commercialization of the chemical process for the production of Nevirapine, a widely prescribed anti-viral medication for the treatment of AIDS. Dr. Gupton’s research group is currently focused on the development and evaluation of new heterogeneous catalysts that can be incorporated into continuous flow reactor systems for pharmaceutical applications.
AbstractThe Medicines for All Initiative employs an interdisciplinary approach to chemical process development that holistically examines the chemical structure of drug targets and determines a set of low cost starting materials that can be used to assemble the molecule. The team then defines the best chemistry and technology to develop the lowest cost manufacturing route. Continuous automation and system monitoring capabilities are integrated with the new chemistry to further reduce direct costs, which provides an agnostic platform for active pharmaceutical ingredient (API) process development. These principals were applied towards the development of a low cost process for nevirapine, the active ingredient in a widely prescribed treatment for HIV-infected patients. The streamlined synthesis includes the preparation of the two pyridine precursors from very low cost raw materials. The condensation of the two pyridine fragments and subsequent cyclization into the drug substance is carried out in a single unit operation in high yield.

 
 
 
Advertisement
 

Recommended Videos

TSE Explores Drug Discovery – Testing a Drug Compound: Clinical Trials

Video

In this episode we speak with Dr Stephen Wright, Consultant in Medicines Development from Limber Strategic, who talks to us about the clinical development of a drug, including how clinical trials are designed and the role of regulatory authorities in the process.

WATCH NOW

TSE Explores Drug Discovery – Identifying and Optimizing a Promising Drug

Video

In this episode we speak with Professor Paul Brennan from the University of Oxford about lead optimization, what to consider when designing a new drug, and much more.

WATCH NOW

TSE Explores Drug Discovery – How Are Drugs Developed?

Video

In this episode, we speak with Tomasz Kostrzewski, Director of Biology at CN Bio about how drugs are developed, including the challenges faced when designing and developing a drug, how drug discovery has evolved, and what trends we can expect to see in the future.

WATCH NOW

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE